Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy
Sponsor: Susan G. Komen Breast Cancer Foundation
A PHASE1 clinical study on Triple Negative Breast Cancer and Triple Negative Breast Neoplasms, this trial is completed. The trial is conducted by Susan G. Komen Breast Cancer Foundation and has accumulated 13 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 8 earlier versions
-
Nov 2019 — Aug 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jul 2019 — Nov 2019 [monthly]
Recruiting PHASE1
-
Sep 2018 — Jul 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE1
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Mar 2017 — Sep 2017 [monthly]
Recruiting PHASE1
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Jun 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Susan G. Komen Breast Cancer Foundation
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .